Corporate Presentation November 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successf ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President & Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Joon Lee - Truist Andy Hsieh - William Blair Thomas Smith - SVB Securities Yale Jen - Laidlaw Scott Henry - ROTH Capital Justin Zelin - BTIG Naz Rahman - Maxim Group Operator Welcome to the Viking T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2022 Results Conference Call July 27, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager of Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joseph Pantginis - H.C. Wainwright Andy Hsieh - William Blair Jay Olson - Oppenheimer Yale Jen - Laidlaw & Company Operator Welcome to the Viking Therapeutics 2022 Second Quarter Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Jay Olson – Oppenheimer Steven Seedhouse – Raymond James Joe Pantginis – H.C. Wainwright Scott Henry – ROTH Capital Yale Jen – Laidlaw & Company Andy Hsieh – William Blair Justin Zelin – BTIG Operator Good day and welcome to the Vi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Corporate Presentation March 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

/IKĭNG THERAPEUTICS Corporate Presentation February 2022 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2021 Earnings Conference Call February 9, 2022 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Les Sulewski - Truist Securities Joe Pantginis - HC Wainwright Jay Olson - Oppenheimer Alexandra Ramsey - William Blair Yale Jen - Laidlaw & Co. Scott Henry - Roth Capital Mike Kratky - SVB Leerin ...